SKINBIO THERAP LS-01
SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the sympt… Read more
SKINBIO THERAP LS-01 (5KW) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, SKINBIO THERAP LS-01 (5KW) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
SKINBIO THERAP LS-01 - Net Assets Trend (None–None)
This chart illustrates how SKINBIO THERAP LS-01's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SKINBIO THERAP LS-01 (None–None)
The table below shows the annual net assets of SKINBIO THERAP LS-01 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to SKINBIO THERAP LS-01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
SKINBIO THERAP LS-01 Competitors by Market Cap
The table below lists competitors of SKINBIO THERAP LS-01 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NanoRepro AG
XETRA:NN6
|
$16.84 Million |
|
Peninsula Land Limited
NSE:PENINLAND
|
$16.84 Million |
|
B3 CONSULTING GRP AB O.N.
F:B37
|
$16.85 Million |
|
Flux Power Holdings Inc
NASDAQ:FLUX
|
$16.85 Million |
|
Inin Group A/S
OL:ININ
|
$16.82 Million |
|
FNC Entertainment Co Ltd
KQ:173940
|
$16.82 Million |
|
Anteotech Ltd
AU:ADO
|
$16.82 Million |
|
Applus Services S.A
PINK:APLUF
|
$16.82 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SKINBIO THERAP LS-01's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares SKINBIO THERAP LS-01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently SKINBIO THERAP LS-01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares SKINBIO THERAP LS-01's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SKINBIO THERAP LS-01 (5KW) | €- | N/A | N/A | $16.83 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |